Safety and feasibility of ultrasound-accelerated catheter-directed thrombolysis in XXXX .

@entity1 @entity1151 @entity1150 @entity432 @entity10067 @entity715
OBJECTIVE: One in four @entity1 with primary iliofemoral @entity1150 ( @entity1150 ) develops @entity715 ( @entity715 ) within 1 year despite optimal standard anticoagulant therapy. Removal of @entity715 by thrombolytic drugs may prevent @entity715 . The aim of this study was to assess the short-term safety and efficacy of ultrasound-accelerated catheter-directed thrombolysis (US-accelerated @entity10067 ). DESIGN: This was a prospective non-randomised interventional study with US-accelerated @entity10067 for @entity1150 . @entity1 AND METHODS: Twelve @entity1 with @entity1150 (seven caval-iliofemoropopliteal, three iliofemoropopliteal, one femoropopliteal and one superior @entity715 ) receiving standard anticoagulant and compression therapy, were treated with additional US-accelerated @entity10067 (13 procedures) using the EKOS Endowave(  ) system (EKOS Corporation, Bothell, WA, USA) between October 2008 and January 2010. RESULTS: Thrombolysis was successful in 85% (11/13), with complete clot lysis (>90% restored patency) and in one case with partial clot lysis (50-90% restored patency). No @entity1151 and one bleeding at the catheter-insertion site were observed. In three @entity1 , underlying lesions were successfully treated with balloon angioplasty and stent insertion. Four @entity1 developed early recurrent @entity715 due to untreated residual @entity432 . CONCLUSION: US-accelerated @entity10067 is a safe and promising treatment in @entity1 with @entity1150 . Residual @entity432 should be treated by angioplasty and stent insertion to avoid early re- @entity715 .
